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OBJECTIVE — The objective of this study was to determine maternal hormonal and meta-
bolic factors associated with insulin sensitivity in human pregnancy.
RESEARCH DESIGN AND METHODS — This was a prospective observational cross-
sectional study of 180 normal pregnant women, using samples collected at the time of a blinded
oral glucose tolerance test (OGTT) between 24 and 32 weeks’ gestation as an ancillary to the
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. The study was conducted at
two public university teaching hospitals, Cleveland, Ohio, and Brisbane, Australia. Fasting
maternal serum cholesterol, triglycerides, free fatty acids, insulin, leptin, tumor necrosis fac-
tor-,placentalgrowthhormone(PGH),insulin-likegrowthfactors(IGFs)1and2,andinsulin-
like growth factor binding proteins (IGFBPs) 1 and 3 were assayed. Correlation and multiple
regression analyses were used to determine factors associated with maternal insulin sensitivity
(IS) estimated using both OGTT-derived (ISOGTT) and fasting (using the homeostasis model
assessment [HOMA]; ISHOMA) insulin and glucose concentrations.
RESULTS — Insulin sensitivity correlated (r  x and y for ISOGTT and ISHOMA, respectively)
with fasting maternal serum leptin (0.44 and 0.52), IGFBP1 (0.42 and 0.39), and triglycer-
ides (0.31 and 0.27). These factors were signiﬁcantly associated with insulin sensitivity in
multiple regression analyses (adjusted R
2 0.44 for ISOGTT and ISHOMA). These variables ex-
plained more than 40% of the variance in estimates of insulin sensitivity.
CONCLUSIONS — Maternal hormonal and metabolic factors related to the placenta, adi-
pose tissue, and the growth hormone axis are associated with the variation in insulin sensitivity
seen during normal human pregnancy.
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T
hedevelopmentofinsulinresistance
in pregnancy has been recognized
formanyyears,butthecausalmech-
anismsremainunclear.Ryanetal.(1)ﬁrst
demonstrated a 40% decrease in insulin
sensitivity in women with gestational di-
abetes as compared with a control group
at term. Later, Catalano at al. (2) con-
ﬁrmed these results describing longitudi-
nal changes in insulin sensitivity and
insulin response in women with normal
glucosetoleranceandgestationaldiabetes
before and during pregnancy. Despite a
general tendency to attribute whole-body
insulin resistance in pregnancy to placen-
talhormones(3),theprecisecontribution
of various hormonal factors remains
poorly deﬁned. Human placental lacto-
gen was an early candidate, although
ﬁndings have been variable (4). Kirwan et
al. (5) have suggested an important role
for tumor necrosis factor (TNF)-,
whereas placental growth hormone
(PGH) has been shown to induce insulin
resistance in a mouse model (6) and to
correlate with maternal glycemia in pa-
tients with diabetes (7). Our study was
designed to further explore the maternal
metabolic and hormonal correlates of in-
sulin resistance in a healthy pregnant
population. We hypothesized that factors
in addition to placental hormones were
associated with insulin resistance during
normal pregnancy.
RESEARCH DESIGN AND
METHODS— The protocol was ap-
proved by the Hospital Institutional Re-
view Board and the Scientiﬁc Review
Committee of the General Clinical Re-
search Center (GCRC) at Metro Health,
Cleveland, Ohio, and by the Human Re-
search Ethics Committee of Mater Health
Services, South Brisbane, Australia. Both
of these centers participated in the inter-
national multicenter Hyperglycemia and
Adverse Pregnancy Outcome (HAPO)
study (8), and subjects consented in writ-
ing both to the main HAPO study and to
this ancillary study. Subjects and investi-
gators were blinded to the results of the
oral glucose tolerance test (OGTT), so as
not to affect the outcome of the primary
HAPO project.
For this ancillary study 180 women
enrolled in HAPO, including 80 from
Cleveland, Ohio, were recruited. Their
characteristics are shown in Table 1. A
75-g OGTT was performed after 8–10 h
overnight fasting in all subjects between
24 and 28 weeks (as close as possible to
the 28th week) of gestation according to
standardized procedures. The OGTT
consisted of 0- (fasting), 60-, and 120-
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and 60-min C-peptide determinations.
Ancillary study patients had estimations
ofseruminsulinat0,60,and120min.As
part of the HAPO protocol, subjects were
unblinded if fasting plasma glucose level
was105mg/dl(5.8mmol/l),2-hOGTT
plasma glucose 200 mg/dl (11.1 mmol/
l), or any recorded value 45 mg/dl (2.5
mmol/l).Thisstudyincludesonlywomen
whose OGTT results were within HAPO
limits. Three women would have been
classiﬁedashavinggestationaldiabetesby
the National Diabetes Data Group criteria
and eight by the Carpenter Coustan crite-
ria (9). However, because all glucose re-
sults were blinded, we have not excluded
these women from this report. Other hor-
monal and metabolic factors were mea-
sured in the fasting state.
GlucoseassaysinHAPOusedtheglu-
cose oxidase method and were carefully
standardized across all HAPO centers
under the supervision of the central labo-
ratoryinBelfast,U.K.Theotherbiochem-
ical and hormonal assays for this ancillary
study were performed at either the GCRC
Cleveland(insulin,leptin,freefattyacids,
TNF-, and insulin-like growth factors
[IGFs] 1 and 2) or Mater Health Services
Brisbanelabs(PGH,IGFbindingproteins
[IGFBPs]1and3,cholesterol,andtriglyc-
erides) in one or two batches, with one
shipment of samples in each direction.
Samples with hemolysis were excluded
prior to testing. All assays were performed
in duplicate. Assay coefﬁcients of variation
(CVs) are shown in supplementary Table
1A in the online appendix, available at
http://care.diabetesjournals.org/cgi/content/
full/dc09-1196/DC1.
Insulin samples were centrifuged at
4°C and stored at 70°C. Insulin was as-
sayed using a double-antibody radioim-
munoassay (Linco, St. Charles, MO) as
previouslydescribed(2).Leptin,freefatty
acids,TNF-,IGF1,IGF2,PGH,IGFBP1,
and IGFBP3 were assayed using previ-
ously described methods (5,7,10).
BasedonpreviousworkbytheCleve-
landgroup(11)theinsulinsensitivity(IS)
indexcalculatedfromtheOGTT(ISOGTT)
according to the equation ﬁrst described
by Matsuda and DeFronzo formed our
primary measure of insulin sensitivity.
Speciﬁcally, insulin sensitivity was calcu-
lated as follows: ISOGTT  10,000/
(FPG)  (FPI)  (G  I); where FPG
and FPI are fasting plasma glucose (mg/
dl)andinsulin(U/ml),respectively,and
G and I are mean glucose and mean insu-
lin, respectively, of all samples from
0–120 min. We also calculated the sim-
pler homeostasis model assessment
(HOMA) measure based on fasting sam-
ples only (ISHOMA) (11). In this case, in-
sulin sensitivity is calculated as ISHOMA 
405 / (FPG  FPI).
Statistical methods
The distributions of all variables were
testedusinganalysisofskewnessandkur-
tosis. Maternal characteristics (supple-
mentary Table 1A) and the dependent
variables ISOGTT and ISHOMA were nor-
mally distributed, but all other biochem-
ical variables required log transformation
to approximate a normal distribution.
Natural logarithms have been used in fur-
ther analyses.
We used linear product moment
(Pearson) correlations followed by multi-
ple linear regression analysis to explore
the relationships between variables. De-
pendent variables were ISOGTT and
ISHOMA. Independent variables included
all measured maternal biochemical pa-
rameters, maternal prepregnancy BMI,
BMI at the OGTT, age, and center (Cleve-
land vs. Brisbane). Results reported in-
cludestandardizedregressioncoefﬁcients
(	) with 95% CIs and partial correlation
coefﬁcients. STATA (StataCorp, College
Station, TX) and Statistica (StatSoft,
Tulsa, OK) were used for statistical anal-
yses. Signiﬁcance was accepted at the 5%
level on two-tailed testing.
RESULTS— Thecharacteristics(means

 SD) of the 180 women who partici-
patedinthisstudyareoutlinedinTable1.
The median (interquartile range) for the
biochemical and hormonal variables are
also shown in Table 1. Only age at deliv-
ery differed between the Cleveland and
Brisbane participants. Non-Hispanic
whites were the predominant ethnic
group (80%), with Hispanics 3%, Asians
9%, and other ethnicities 8%. The sub-
jects’ mean prepregnancy BMI was in the
overweight range. Mean gestation at the
timeofOGTTwasveryclosetotheHAPO
goal of 28 weeks. The Pearson correlation
coefﬁcients between maternal biochemi-
cal variables, estimates of insulin resis-
tance, and maternal BMI (prepregnancy
andattheOGTTvisit)areshowninTable
2. BMI, IGFBP1, triglycerides, and leptin
correlated signiﬁcantly with the estimates
of maternal insulin sensitivity.
Subsequently, multiple regression
analyses were performed. Results are re-
ported for ISOGTT in Table 3. Maternal
BMI calculated at the OGTT visit, al-
though signiﬁcant in simple correlations
(Pearson r  0.47, 0.48 for BMI vs.
ISOGTT and ISHOMA, respectively), be-
came not statistically signiﬁcant after ad-
justing for the other variables in the
model. Models incorporating prepreg-
nancy BMI rather than BMI at the OGTT
showed essentially the same ﬁndings. As
can be seen from Table 3, the model in-
corporating all biochemical variables ac-
counted for 44% of the observed variance
in ISOGTT. Multiple regression ﬁndings
for ISHOMA were virtually identical (mul-
tiple R
2 0.48, adjusted R
2 0.44; P 
0.0001) and are not shown separately.
Leptin, IGFBP1, and triglycerides were
Table 1—Maternal characteristics and biochemical variables
Age at delivery (years) 29.1 
 5.5
Prepregnancy weight (kg) 71.1 
 18.6
Prepregnancy BMI (kg/m
2) 26.2 
 6.4
Gestation at OGTT (weeks) 27.9 
 1.6
Weight at OGTT (kg) 81.3 
 18.4
BMI at OGTT (kg/m
2) 30.0 
 5.9
IGFBP1 (nmol/l) 6.18 (3.30–5.69)
IGFBP3 (nmol/l) 141.50 (95.55–184.49)
PGH (ng/ml) 10.11 (5.94–12.48)
Cholesterol (mmol/l) 6.18 (5.52–6.82)
Triglycerides (mmol/l) 2.02 (1.56–2.28)
Leptin (ng/ml) 35.92 (21.01–45.43)
Free fatty acids (mmol/l) 0.59 (0.47–0.71)
TNF- (pg/ml) 2.50 (0.87–2.83)
IGF1 (ng/ml) 164.32 (25.14–276.60)
IGF2 (ng/ml) 893.34 (770.69–1,050.41)
Data are means 
 SD or median (interquartile range). Clinical characteristics of women who participated in
the study (presented as means 
 SD) were normally distributed. Biochemical and hormonal variables
measured in the study (presented as median interquartile range) were nonnormally distributed and were
transformed as natural logarithms for further analyses.
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tivity estimates. These ﬁndings were not
altered by exclusion of those participants
who would have been classiﬁed as suffer-
ing from gestational diabetes by the Na-
tional Diabetes Data Group or Carpenter
Coustan criteria.
To determine whether maternal over-
weight/obesity inﬂuenced the factors as-
sociated with insulin sensitivity, we
repeatedtheregressionanalyseswithpar-
ticipants characterized by prepregnancy
BMI less than or more than 25 kg/m
2.B e -
cause the relationship between BMI and
fat mass may vary across ethnic groups,
we also repeated all analyses using only
thoseparticipantsfromthedominanteth-
nic group (non-Hispanic whites). Both
the stratiﬁed and non-Hispanic white
only BMI analyses gave very similar re-
sults to those presented for the whole co-
hort, and the data are not presented
separately. The other ethnic subgroups
were considered too small for separate
analysis. Differences in the relationship
between BMI, adiposity, and leptin con-
centrations between ethnic groups may
explain in part why leptin and not BMI
has a stronger correlation with estimates
of insulin resistance.
CONCLUSIONS— Thecurrentstudy
demonstrates that a substantial propor-
tion of the variance in maternal insulin
sensitivityinpregnancyisassociatedwith
variations in maternal biochemical vari-
ables related to the placenta (leptin) adi-
pose tissue (leptin and triglycerides) as
well as the growth hormone axis (IG-
FBP1). The placenta is a major source of
leptin in pregnancy and also the source of
high concentration of PGH, which up-
regulates the growth hormone/IGF axis
duringpregnancy(7,12).Althoughleptin
is produced both in placenta and adipose
tissue, several lines of evidence suggest
that the major changes in leptin during
pregnancy relate to placental leptin pro-
duction (13). First, maternal leptin de-
creases abruptly after delivery of the
placenta. Second, there is no correlation
between change in maternal BMI and lep-
tin. Third, the pregnancy-related increase
in maternal leptin predates increased fat
mass in pregnancy (13). In a longitudinal
study the Cleveland group (14) has also
demonstrated a close correlation between
serum leptin and fat oxidation during
early and late pregnancy but not in the
nonpregnant state. This provides a fur-
ther mechanism by which leptin may in-
ﬂuence maternal insulin sensitivity.
Recentevidencedemonstratesthatmater-
nal obesity also inﬂuences both placental
and circulating monocyte/macrophage
populations and inﬂammatory markers
(15), suggesting that adipose and placen-
tal tissue contributions to the overall ma-
ternalmetabolicandinﬂammatorymilieu
are interlinked.
Interestingly, the inverse relationship
ofmaternalBMItoinsulinsensitivity,well
recognized in many studies, was no
longer statistically signiﬁcant in our
model when the panel of 10 biochemical
and hormonal variables were included.
Although these parameters are, in them-
selves, signiﬁcantly correlated with ma-
ternal BMI (Table 2), they appeared more
strongly related to insulin sensitivity in
the multiple regression analyses.
An etiologic role has been proposed
forreductioninIGFBP1asalinkbetween
maternal obesity and increased birth
weight through increased bioactive IGF1
in maternal serum (16,17). Conﬁrming
these previous ﬁndings, our study dem-
onstrated a negative correlation between
maternal BMI and IGFBP1. Reduced IG-
FBP1 in women with higher BMI would
be predicted to increase free maternal
IGF1andpromotenutrienttransfertothe
fetus and fetal growth. Indeed, IGFBP1
has been reported to be negatively corre-
lated with fetal lean body mass, though
not with fat mass (18), suggesting a spe-
ciﬁc effect on fetal body composition.
PGH showed a weak negative corre-
Table 2—Pearson correlation coefﬁcients among insulin sensitivity estimates, BMI, and bio-
chemical variables
ISOGTT ISHOMA
Prepregnancy
BMI
BMI at OGTT
visit
Prepregnancy BMI 0.415* 0.410* 1.000 0.940*
BMI at OGTT visit 0.470* 0.484* 0.940* 1.000
IGFBP1 0.421* 0.386* 0.316* 0.360*
IGFBP3 0.002 0.043 0.0390 0.039
PGH 0.041 0.005 0.198† 0.223*
Cholesterol 0.047 0.076 0.123 0.096
Triglycerides 0.311* 0.269* 0.159† 0.106
Leptin 0.437* 0.519* 0.448* 0.550*
Free fatty acids 0.051 0.006 0.0462 0.052
TNF- 0.023 0.0390 0.0128 0.039
IGF1 0.055 0.027 0.0434 0.053
IGF2 0.104 0.033 0.0550 0.036
Pearson correlation coefﬁcients between calculated maternal BMI (prepregnancy and at the OGTT visit),
biochemical, and hormonal parameters measured in the study (transformed to natural logarithms) and
estimates of insulin sensitivity (ISOGTT and ISHOMA). *P  0.01; †P  0.05.
Table 3—Regression model: dependant variable ISOGTT
	 95% CI (	)
Partial
correlation P
Leptin 0.365 0.535 to 0.195 0.330 0.001
IGFBP1 0.319 0.180 to 0.458 0.349 0.001
Triglycerides 0.293 0.432 to 0.155 0.327 0.001
PGH 0.136 0.286 to 0.015 0.146 0.076
BMI at OGTT visit 0.142 0.311 to 0.028 0.135 0.100
Cholesterol 0.096 0.045 to 0.238 0.110 0.181
Center 0.160 0.457 to 0.137 0.088 0.288
Maternal age 0.063 0.061 to 0.188 0.082 0.317
IGF1 0.078 0.359 to 0.203 0.045 0.584
IGFBP3 0.016 0.206 to 0.174 0.014 0.870
Free fatty acids 0.006 0.141 to 0.130 0.007 0.935
TNF- 0.003 0.143 to 0.149 0.003 0.967
IGF2 0.001 0.179 to 0.176 0.001 0.989
Summary of multivariable regression of biochemical and other parameters associated with estimates of
insulin sensitivity (ISOGTT and ISHOMA). Standardized correlation coefﬁcients (	) and their 95% CIs as well
as partial correlations are shown for each variable. Overall multiple R
2 0.49; adjusted R
2 0.44; P  0.0001.
Insulin sensitivity in pregnancy
358 DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 care.diabetesjournals.orglation with insulin sensitivity in the mul-
tiple regression analysis, but this failed to
reach statistical signiﬁcance (P  0.076).
A negative relationship of PGH with insu-
lin sensitivity would be predicted from
known growth hormone actions in the
nonpregnant state and with ﬁndings of
decreased insulin sensitivity related to el-
evated PGH in a transgenic mouse model
(6).OnepreviousstudybyFuglsangetal.
(19) also found no correlation between
PGH and fasting insulin sensitivity esti-
mated just prior to delivery. The effects of
PGH thus appear (at best) modest in nor-
mal human pregnancy. Other factors are
clearly of greater importance.
Previous ﬁndings regarding the rela-
tionship of maternal hormones and adi-
pokines to insulin sensitivity have been
variable.Usingthefrequentlysampledin-
travenous glucose tolerance test (IVGTT)
in a small group of patients (n  38),
McLachlan et al. (12) reported that leptin
correlated negatively with insulin sensi-
tivity, but adiponectin, TNF-, and C-re-
active protein proved unrelated to insulin
sensitivity. In contrast, one previous re-
port of 15 pregnant women using the in-
sulin clamp (5) from our group noted
TNF- as a signiﬁcant factor. However,
subjects in that study included obese
womenwithgestationaldiabeteswhoalso
had signiﬁcantly elevated plasma TNF-
during pregnancy. Partitioning of TNF-
may also be of importance in this regard.
The recent study from Challier et al. (15)
demonstrated increased TNF- in pe-
ripheral blood and placental mononu-
clear cells, associated with insulin
resistance, in obese pregnant women, but
no changes were noted in maternal
plasma TNF-. In the current study, we
did not ﬁnd any association of TNF-
with insulin sensitivity. A further recent
study from Mastorakos et al. (20) con-
ﬁrmed a relationship between leptin and
insulin resistance, reported no relation-
ship of insulin resistance with adiponec-
tin, and noted an association of insulin
sensitivity with yet another adipocyto-
kine, visfatin. The often divergent ﬁnd-
ings about relationships among
adipocytokines, BMI, and insulin sensi-
tivity are summarized in a recent review
by Briana et al. (21).
Do the correlations described in our
studyrepresentunderlyingcausesofvari-
ations in maternal insulin sensitivity in
pregnancy or merely the consequences of
such variations? A causal role seems pos-
sible for IGFBP1 as described above. Lep-
tin has been noted to directly modulate
insulin sensitivity in vitro (22) and has
been described as a predictor of gesta-
tional diabetes independent of maternal
BMI (23). Pregnancy is a physiological
leptin-resistant state because increased
maternal energy intake and positive en-
ergy balance develop in late pregnancy
despite increased leptin levels, which
would be predicted to reduce appetite
and energy intake in a fully leptin-
sensitive state (13). Leptin has also been
reported to reduce insulin secretion in
both rodent and human islets in vitro
(24).However,theuniformhyperinsulin-
emia of normal pregnancy despite high
leptin concentrations again suggests lep-
tin resistance at the level of the 	-cells.
Partitioning effects may also be important
for leptin because it has been noted that
placental leptin mRNA and protein con-
tent is three- to ﬁvefold higher in type 1
diabetic pregnancies than in those of con-
trol subjects, despite comparable mater-
nal serum leptin concentrations (13).
In summary, our data demonstrate
that variations in maternal insulin sensi-
tivityinnormalpregnancyrelateinpartto
the maternal adipocytokine and growth
hormone/IGF axes. Our ﬁndings are
novel in that they extend the range of po-
tential factors examined simultaneously
in relation to maternal insulin sensitivity
andincludeamuchlargernumberofsub-
jects than in most previous reports. We
acknowledge that estimation of insulin
sensitivityusingtheISOGTTandISHOMAis
less precise than gold-standard measure-
ment with an insulin clamp, but we
wouldconsiderthatclampstudiesarenot
feasible in a cohort of this size. Further,
we have established strong correlations
with the clamp method in previous
studies.
It is plausible, though not yet proven,
that these systems serve to regulate
whole-body insulin sensitivity in individ-
ual pregnant women. An improved un-
derstanding of these factors may
potentially open new avenues of treat-
ment in gestational diabetes and other
conditions associated with insulin resis-
tance in pregnancy, such as obesity and
preeclampsia.
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